News
PSTV
--
0.00%
--
Plus Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on April 22, 2021
AUSTIN, Texas, April 08, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, announced that ...
GlobeNewswire · 2d ago
Plus Therapeutics Stock Shows Every Sign Of Being Significantly Overvalued
GuruFocus News · 03/30 21:21
Plus Therapeutics Stock Shows Every Sign Of Being Significantly Overvalued
GuruFocus News · 03/30 08:13
Plus Therapeutics and Piramal Pharma ink master services agreement
Piramal Pharma's Contract Development and Manufacturing Organization, Piramal Pharma Solutions entered into a Master Services Agreement ((MSA)) with Plus Therapeutics ([[PSTV]] -3.6%) for the former to perform services related to the
Seekingalpha · 03/24 16:15
ViacomCBS, GameStop among premarket losers' pack
Benitec Biopharma (BNTC) -21%.Second Sight Medical Products (EYES) -21% on $28M capital raise.Takung Art (TKAT) -17%.Evolve Transition Infrastructure (SNMP) -15%.GameStop (GME) -14% on Q4 earnings release.CASI Pharmaceuticals (CASI) -12% after proposes sto...
Seekingalpha · 03/24 12:19
ORMP, MOGO, LIZI and LEAF among premarket gainers
Benitec Biopharma (BNTC) +132%.Evolve Transition Infrastructure (SNMP) +115%.Plus Therapeutics (PSTV) +46% on Rhenium NanoLiposome deal.Oramed Pharmaceuticals (ORMP) +29%.China Jo-Jo Drugstores (CJJD) +25%.Hoth Therapeutics (HOTH) +21% on positive preclini...
Seekingalpha · 03/23 12:23
Plus Therapeutics (PSTV) shares surge 48% on Rhenium NanoLiposome deal
Plus Therapeutics (PSTV) soars 48% premarket after entering into a master services agreement ((MSA)) with Piramal Pharma Solutions ((PPS)) for the development, manufacture, and supply of Plus’ Rhenium NanoLiposome ((RNL)) intermediate drug
Seekingalpha · 03/23 11:41
BRIEF-Plus Therapeutics Inc Entered Into A Master Services Agreement With Piramal Pharma Solutions
reuters.com · 03/23 11:37
Plus Therapeutics Enters Into Master Services Agreement With Piramal Pharma Solutions; Financial Details Not Disclosed
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that it has
Benzinga · 03/23 11:34
Plus Therapeutics Enters Into Master Services Agreement with Piramal Pharma Solutions, a Leading Contract Development and Manufacturing Organization
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that it has entered into a master services agreement (MSA) with Pi...
GlobeNewswire · 03/23 11:30
Plus Therapeutics Inc. (NASDAQ: PSTV) Featured in Virtual Coverage of Investor Summit Group's Q1 Virtual Summit
Mar 22, 2021 (Investor Brand Network via COMTEX) -- Plus Therapeutics Inc. (NASDAQ: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic...
Investor Brand Network · 03/22 18:44
Plus Therapeutics, Inc. to Participate in Upcoming Virtual Conferences
AUSTIN, Texas, March 18, 2021 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that Marc Hedrick...
GlobeNewswire · 03/18 13:30
SIFY, WTI, OPEN and EVFM among notable midday movers
Gainers: Second Sight Medical Products (EYES) +337%.AMTD International (HKIB) +27%.Sify Technologies Limited (SIFY) +26%.Boqii Holding Limited (BQ) +25%.ChromaDex Corporation (CDXC) +22%.W&T Offshore (WTI) +21%.Anchiano Therapeutics (ANCN) +18%.Purple Inno...
Seekingalpha · 03/05 17:36
Insider Buys Plus Therapeutics Shares
Plus Therapeutics Inc (NASDAQ:PSTV) was trading 8.1% higher from the previous closing price. Hedrick Marc H filed a Form 4 with the SEC on Friday, March 5. The insider bought 2,500 shares at an average price of $2.50. After the transaction, the executive's...
Benzinga · 03/05 16:51
Insider Buys Plus Therapeutics Stock
 
Benzinga · 03/04 16:04
Plus Therapeutics to Participate in Upcoming Virtual Conferences
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of ...
GlobeNewswire · 03/03 12:30
Nextech Successfully Launches its Ad Network Featuring Augmented Reality Capabilities on its Virtual Events Properties, Delivering Millions of Impressions
Nextech AR Solutions ("Nextech'' or the "Company") (OTCQB: NEXCF) (NEO: NTAR.NE) (CSE: NTAR) (FSE: N29), a diversified leading provider of virtual and augmented reality (AR) experience technologies and services for eCommerce, education, advertising, confer...
Business Wire · 03/02 12:30
Emerging Growth Conference 2 Announced for March 3, 2021 Niche Companies in Technology, AR, eCommerce, Beverage and more in Attendance
GlobeNewswire · 03/01 12:30
Nextech AR Solutions to Present at the Emerging Growth Conference on March 3, 2021
Business Wire · 03/01 12:30
BRIEF-Plus Therapeutics Files Prospectus Relates To Offer And Sale Of Up To 4.5 Mln Shares Of Co's Common Stock
reuters.com · 02/26 21:34
Webull provides a variety of real-time PSTV stock news. You can receive the latest news about Plus Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About PSTV
Plus Therapeutics, Inc., formerly Cytori Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The Company is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The Company is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma.